Net profit of Akums Drugs & Pharmaceuticals rose 1.75% to Rs 66.32 crore in the quarter ended December 2025 as against Rs 65.18 crore during the previous quarter ended December 2024. Sales rose 14.76% to Rs 1159.59 crore in the quarter ended December 2025 as against Rs 1010.41 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1159.591010.41 15 OPM %12.6612.01 - PBDT157.45130.79 20 PBT117.8086.27 37 NP66.3265.18 2 Powered by Capital Market - Live News

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live News

Akums Drugs & Pharmaceuticals has received European GMP certificates for its two facilities, Plant 1 and Plant 2, both located at Haridwar, Uttarakhand. While the certification for Plant 1 represents a renewal of its existing EU-GMP approval, Plant 2 has received EU-GMP certification for the first time. Powered by Capital Market - Live News

Net profit of Akums Drugs & Pharmaceuticals declined 37.46% to Rs 40.78 crore in the quarter ended September 2025 as against Rs 65.21 crore during the previous quarter ended September 2024. Sales declined 1.51% to Rs 1017.53 crore in the quarter ended September 2025 as against Rs 1033.09 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1017.531033.09 -2 OPM %9.2811.73 - PBDT103.54122.75 -16 PBT65.6787.89 -25 NP40.7865.21 -37 Powered by Capital Market - Live News

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live News